CN113383013A - 一种人白细胞介素2变体或其衍生物 - Google Patents
一种人白细胞介素2变体或其衍生物 Download PDFInfo
- Publication number
- CN113383013A CN113383013A CN201980072296.9A CN201980072296A CN113383013A CN 113383013 A CN113383013 A CN 113383013A CN 201980072296 A CN201980072296 A CN 201980072296A CN 113383013 A CN113383013 A CN 113383013A
- Authority
- CN
- China
- Prior art keywords
- seq
- variant
- derivative
- mutation
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
提供了具有一个或多个氨基酸突变的人白细胞介素‑2(IL‑2)变体或其衍生物,所述IL‑2变体或其衍生物与野生型IL‑2相比,具有增加的稳定性,并具有用作免疫治疗剂的改善特性。还公开了包含所述人IL‑2变体或其衍生物的免疫缀合物、药物组合物、编码其的多核苷酸分子、载体、宿主细胞和制备方法,以及所述IL‑2变体或其衍生物、包含其的免疫缀合物或药物组合物的制药用途。
Description
PCT国内申请,说明书已公开。
Claims (20)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018115709305 | 2018-12-21 | ||
CN201811570930 | 2018-12-21 | ||
CN201910158957 | 2019-03-04 | ||
CN2019101589571 | 2019-03-04 | ||
PCT/CN2019/126901 WO2020125743A1 (zh) | 2018-12-21 | 2019-12-20 | 一种人白细胞介素2变体或其衍生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113383013A true CN113383013A (zh) | 2021-09-10 |
CN113383013B CN113383013B (zh) | 2022-11-04 |
Family
ID=71102517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980072296.9A Active CN113383013B (zh) | 2018-12-21 | 2019-12-20 | 一种人白细胞介素2变体或其衍生物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220056094A1 (zh) |
EP (1) | EP3875475A4 (zh) |
JP (1) | JP2022513265A (zh) |
KR (1) | KR20210107714A (zh) |
CN (1) | CN113383013B (zh) |
AU (1) | AU2019409196A1 (zh) |
BR (1) | BR112021010983A2 (zh) |
CA (1) | CA3123471A1 (zh) |
MX (1) | MX2021007085A (zh) |
TW (1) | TW202034945A (zh) |
WO (1) | WO2020125743A1 (zh) |
ZA (1) | ZA202103785B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023046156A1 (en) * | 2021-09-26 | 2023-03-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Il-2 variants and fusion proteins thereof |
CN116041539A (zh) * | 2022-10-31 | 2023-05-02 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
WO2024083097A1 (zh) * | 2022-10-19 | 2024-04-25 | 北京志道生物科技有限公司 | 一种il-2突变体 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202128961A (zh) | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
CN114380919B (zh) * | 2020-10-18 | 2024-06-25 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
CA3201446A1 (en) * | 2020-11-13 | 2022-05-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof |
CN113831402A (zh) * | 2021-07-30 | 2021-12-24 | 西安龙腾景云生物科技有限公司 | 一种人白细胞介素2变体及其用途 |
KR20240036511A (ko) * | 2021-07-30 | 2024-03-20 | 윈취안 바이오테크놀로지 (베이징) 씨오., 엘티디. | 인간 인터루킨-2 변이체 및 이의 용도 |
WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
WO2024037572A1 (en) * | 2022-08-16 | 2024-02-22 | Kine Biotech Co., Ltd. | Interleukin-2 variants and their uses in treating cancers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005007121A2 (en) * | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
CN1599867A (zh) * | 2001-12-04 | 2005-03-23 | 默克专利有限公司 | 具有调节的选择性的免疫细胞因子 |
CN103492411A (zh) * | 2011-02-10 | 2014-01-01 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985000817A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US7371371B2 (en) | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
EP1723251A4 (en) * | 2004-03-05 | 2008-04-23 | Novartis Vaccines & Diagnostic | IN VITRO TESTING SYSTEM FOR PREDICTING THE TOLERABILITY OF THERAPEUTIC AGENTS IN PATIENTS |
GB2415904B (en) * | 2005-02-07 | 2006-10-25 | Chiron Corp | Preparing aldesleukin for pharmaceutical use |
WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
CA2749539C (en) | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases |
CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
KR102493543B1 (ko) * | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
EP3411414A4 (en) | 2016-02-05 | 2019-10-23 | Washington University | COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF |
-
2019
- 2019-12-20 EP EP19898340.5A patent/EP3875475A4/en active Pending
- 2019-12-20 MX MX2021007085A patent/MX2021007085A/es unknown
- 2019-12-20 AU AU2019409196A patent/AU2019409196A1/en active Pending
- 2019-12-20 KR KR1020217021450A patent/KR20210107714A/ko unknown
- 2019-12-20 BR BR112021010983-8A patent/BR112021010983A2/pt unknown
- 2019-12-20 TW TW108146978A patent/TW202034945A/zh unknown
- 2019-12-20 JP JP2021534744A patent/JP2022513265A/ja active Pending
- 2019-12-20 CA CA3123471A patent/CA3123471A1/en active Pending
- 2019-12-20 CN CN201980072296.9A patent/CN113383013B/zh active Active
- 2019-12-20 US US17/414,062 patent/US20220056094A1/en active Pending
- 2019-12-20 WO PCT/CN2019/126901 patent/WO2020125743A1/zh unknown
-
2021
- 2021-06-02 ZA ZA2021/03785A patent/ZA202103785B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1599867A (zh) * | 2001-12-04 | 2005-03-23 | 默克专利有限公司 | 具有调节的选择性的免疫细胞因子 |
WO2005007121A2 (en) * | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
CN103492411A (zh) * | 2011-02-10 | 2014-01-01 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023046156A1 (en) * | 2021-09-26 | 2023-03-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Il-2 variants and fusion proteins thereof |
WO2024083097A1 (zh) * | 2022-10-19 | 2024-04-25 | 北京志道生物科技有限公司 | 一种il-2突变体 |
CN116041539A (zh) * | 2022-10-31 | 2023-05-02 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
Also Published As
Publication number | Publication date |
---|---|
JP2022513265A (ja) | 2022-02-07 |
EP3875475A4 (en) | 2022-12-07 |
BR112021010983A2 (pt) | 2021-08-31 |
AU2019409196A1 (en) | 2021-06-17 |
TW202034945A (zh) | 2020-10-01 |
ZA202103785B (en) | 2022-07-27 |
CN113383013B (zh) | 2022-11-04 |
MX2021007085A (es) | 2021-08-11 |
US20220056094A1 (en) | 2022-02-24 |
EP3875475A1 (en) | 2021-09-08 |
WO2020125743A1 (zh) | 2020-06-25 |
CA3123471A1 (en) | 2020-06-25 |
KR20210107714A (ko) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113383013B (zh) | 一种人白细胞介素2变体或其衍生物 | |
CN111647068A (zh) | 一种人白细胞介素2变体或其衍生物 | |
EP2467165B1 (en) | Targeted immunoconjugates | |
TWI666027B (zh) | 突變介白素-2多肽 | |
CN103649114A (zh) | 新的免疫缀合物 | |
WO2023169349A1 (zh) | 一种融合蛋白、制备方法及其应用 | |
WO2020228791A1 (zh) | 增殖免疫细胞的il-2突变体蛋白 | |
CN113667004A (zh) | 一种白介素2突变体 | |
CN115057919A (zh) | 一种人白细胞介素2变体及其用途 | |
RU2799437C2 (ru) | Вариант человеческого интерлейкина-2 или его производное | |
WO2022117692A2 (en) | Ph-dependent mutant interleukin-2 polypeptides | |
WO2023005680A1 (zh) | 一种人白细胞介素2变体及其用途 | |
CN116178572A (zh) | 构建嵌合蛋白的嵌合区域、构建方法、嵌合蛋白及其应用 | |
CN109952370A (zh) | 用于产生免疫缀合物的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40051456 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |